Pfizer, BioNTech, Moderna, AstraZeneca; to see who leads the stock market vaccine race | Business

The race for putting the world’s weapons first with an effective covid-19 vaccine it was reflected throughout 2020 in the price of laboratory shares. Is he The positive impact on the papers was so great the more support the company was on the world market before the pandemic begins.

This dynamic is clear when we look at two actions linked to the same vaccine, the first non-state to be applied, initially in the United Kingdom and shortly after in the United States. It was born from the association between the American Pfizer, years ago between the giants of the sector, and BioNTech, until another illustrious unknown day specialized in cancer research.

The shares of the first company rose only 0.27%, between December 31, 2019 and December 24. The roles of the German partner soared 186%, and the company was catapulted into the pantheon of the world’s greatest in an instant.

• It is worth highlighting here a curiosityAccording to the owners of BioNTech, research on a vaccine there began in January, before covid-19 spread around the world. Based on the news, they predicted what could happen from Wuhan, China. The company would not have the legs, alone, to manufacture antidotes on a large scale. Hence the search for Pfizer and the birth of the association.

The biotech company Modern, which also targets 95% effectiveness of its vaccine, had an even bigger jump in roles than the German competitor this year. Also qualified to provide services in the United States, his papers soared 501% in 2020. Have you ever heard of her?

Novavax (“Novav …” who?) Has an even more impressive performance on the stock market.

It’s not every day that a vaccine is so eagerly awaited, let’s agree. It hadn’t happened in a century, with the Spanish flu between 1918 and 1920. From the point of view of companies that have always focused on vaccines, but lack pandemics, Covid-19 is a full plate to devour. With fork and knife in hand Novavax shares have soared since the beginning of the year by 3.149%. It is in the final phase of testing.

And just as the actions of the companies reflect the success of the search for the vaccine, those who skated in the middle of the investigation also left their tracks.

Headlines for the entire pandemic include advanced research from partnership between the University of Oxford, UK, and local pharmacist AstraZeneca. The success of this venture is eagerly awaited, given the various partnerships made between the duo and governments around the world, including the Brazilian. In addition, the doses of the British vaccine would not depend as much on refrigeration as the others, which would facilitate the logistics of its application throughout the planet.

But doubts about British vaccines persist, especially since November. Optimistic data was announced for the month, with effectiveness of antidotes between 62% for those who receive two full doses and 90% for those who receive half a dose and then a full dose.

• Brazil loses race for vaccines in Latin America
• ‘I don’t care’, says Bolsonaro about the delay of the vaccine in Brazil

Was it confusing? AstraZeneca Vice President Mene Pangalos also. In the last stage prior to approval by regulatory bodies, the company admitted errors of analysis, although it guarantees that they do not compromise the success of the antidote. In any case, and even without its vaccine starting to be applied on a large scale around the world, The shares of the company accumulate a fall of 2.69% in the year.

Ahead, with a cumulative increase of 4.52%, are Johnson & Johnson shares. Your subsidiary, Janssen, is also an object of mistrust. Clinical studies of the laboratory vaccine have resumed. But in November, they were interrupted by an “adverse reaction” in a volunteer who received a dose of the antidote. The forecast is for final results in January.

The case of the partnership between the British laboratory GlaxoSmithKline and the French pharmaceutical Sanofi is the most striking collapse.

The actions of GlaxoSmithKline, with a focus on vaccines and other biotech discoveries, plunged 23%. Roles of Sanofi fell 12%. Both announced in December that their immunizer had an insufficient immune response in the elderly, the most prominent risk group in COVID-19. And the completion of his work was postponed to the distant last days of 2021.

• In parallel with the race for a vaccine against the contagion of the coronavirus, There is still the race for an effective remedy against the effects of covid-19 in those who contract it.

And then the skating is even greater. American stocks Gilead Sciences, manufacturer of an antiviral called remdesivir, previously used against Ebola, accumulate a 12% loss in the year. Experimentally and with emergency releases, the drug came to be seen as a potential cure for Covid-19, and today it is administered to patients in the United States, Japan, the United Kingdom and Germany. The World Health Organization (WHO), however, does not recommend use, as it has found no evidence of efficacy..

Shares of German drugmaker Merk fell almost 12%. The company has an antiviral drug and vaccines in testing, and it is behind the competition on both fronts. His leadership, by the way, had said in September that promising a vaccine in 2020 was a disservice. The tongue was burned.

There is an important factor to consider in this poor performance of the actions of the drug manufacturers that fight against the effects of covid-19. Prosperous vaccines, who fight the cause, these drugs become relatively less important. In other words, the old maxim of “better safe than sorry” it is being incorporated into prices.